DXS International plc Trading Statement

 
TIDMDXSP 
 
 
   DXS INTERNATIONAL PLC 
 
   (AQSE: DXSP) 
 
   Trading Update May 2021 
 
   DXS International plc ("DXS", the "Company"), the AQSE quoted clinical 
decision support developer and supplier of clinical decision support 
systems, is pleased to provide shareholders with the following trading 
update. 
 
   For the twelve months ending April 2021, we are pleased to announce that 
we have been able to achieve a similar profit to the year ending 2020 
with turnover marginally improved for the same period. This was due to a 
slight increase in existing sales from both the NHS and the 
Pharmaceutical industry and initial revenue for the Hypertension 
program. Last financial year to 30 April 2020, turnover was GBP3.28m and 
net profit was GBP429k. 
 
   Although launching our new solutions as originally intended has been 
severely hampered due to the COVID pandemic occupying GP's focus, we 
have managed to continue with our pilots, albeit at a slower pace than 
originally envisaged. As Covid related pressure on GPs subsides we 
anticipate that we will be able to progress pilots at a more normal 
pace. 
 
   The feedback obtained so far from the pilots has been excellent with 
positives being highlighted and constructive criticism enabling our 
teams to continue with fixes and enhancements. 
 
   Our process of applying for NHS GPIT Futures accreditation is complete 
with all standards having been approved and we anticipate formal 
accreditation being awarded imminently. This means that Clinical 
Commissioning Groups (CCG's) will be able to procure our ExpertCare 
hypertension solution via a central NHS fund. 
 
   Regarding our international activities, we were sadly not selected for 
phase II of the European Union's Horizon Research and Development 
programme. Although receiving much positive feedback for the quality of 
our submission, the programme has decided to take forward participants 
based in the EU requiring less EU investment. However, we have 
benefitted hugely from being selected for phase I which provided grant 
funding to develop our understanding of the challenges across Europe for 
dealing with Hypertension. This has enabled us to create a detailed 
blueprint for adapting our Hypertension solution to meet these needs and 
address new markets. 
 
   David Immelman, Chief Executive of DXS said: 
 
   "While there are early signs of the healthcare market beginning to 
normalise, GPs and Primary Care staff remain pressured, particularly 
while facing significant backlogs built up during the past 18 months. 
This however has presented an opportunity which is evident by the keen 
interest being shown in our CompleteCare cancer toolkit which can 
potentially assist practices expedite cancer treatment backlogs. 
Although frustrated by delays, our sales and marketing team remain 
focused and we continue to persevere with our sales and marketing 
efforts both in the UK and abroad." 
 
   The Directors of DXS International plc accept responsibility for this 
announcement 
 
   Enquiries: 
 
 
 
 
David Immelman (Chief Executive)            01252 719800 
 DXS International plc             [e-mail] 
https://www.dxs-systems.co.uk 
 
 
 
 
 
 
Corporate Advisor 
City & Merchant 
 David Papworth     020 7101 7676 
 
 
 
 
 
 
Corporate Broker 
Hybridan LLP 
 Claire Louise Noyce   020 3764 2341 
 
 
   Notes to Editors 
 
   About DXS: 
 
   DXS International presents up to date treatment guidelines and 
recommendations, from Clinical Commissioning Groups and other trusted 
NHS sources, to doctors, nurses and pharmacists in their workflow and 
during the patient consultation. This effective clinical decision 
support ultimately translates to improved healthcare outcomes delivered 
more cost effectively and which should significantly contribute towards 
the NHS achieving its projected efficiency savings. 
 
 
 
 

(END) Dow Jones Newswires

May 28, 2021 02:00 ET (06:00 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.